Stocosil is a pharmaceutical company delivering next generation products that treat the double-threat of hypertension and high cholesterol.
Stocosil strikes at the heart of cardiovascular disease with their lead drug product, Kybiqo —a dual-drug pill that simultaneously treats hypertension and high cholesterol, that may reduce risk by a dramatic 45%. Kybiqo is a fixed dose combination of olmesartan medoxomil and rosuvastatin calcium which currently does not exist in the United States.
In addition to Kybiqo, Stocosil has a strong pipeline of products that will tap into a large global market and multi-billion dollar revenue potential.
Stocosil boasts an impressive management team possessing significant experience in drug development.
Stocosil was founded by incubator Autotelic Inc. in December 2014, for the purpose of licensing and commercializing Kybiqo, which is currently marketed in South Korea under the brand name Olostar® by Daewoong Pharmaceuticals.
Stocosil has licensed the rights from Daewoong to commercialize Kybiqo in the United States, Canada, Japan, Taiwan and Australia. The license includes Daewoong’s patent portfolio, comprising a key drug formulation patent.
Our business plan is first to market and sell Kybiqo in the United States, as well as other countries in which we hold a license.
Total accessible U.S. market opportunity of $1-$3 billion.
Positive feedback from FDA. Kybiqo currently sold as Olostar® in South Korea. Data from previous studies available.
Multi-product pipeline targeting unmet clinical needs with large market potential.
Rights to well-defined markets, U.S., Canada, Japan, Taiwan and Australia. Manufacturing and distribution supported by well-established partners.
Patent-protected FDC and technology backed by proprietary and exclusive IP licenses and additional patents.
High caliber management team with extensive industry experience and successful track record in drug development.
We are a pharmaceutical company engaged in the discovery, acquisition, development and commercialization of proprietary drug therapies in the U.S. and foreign territories. Our primary therapeutic focus is hypertension and hypercholesterolemia. We currently have three clinical development programs underway:
ST-101 – FDA approval of Kybiqo, a dual-drug pill treating hypertension and hypercholesterolemia.
ST-102 – FDA approval of our dual-drug pill coupled with a therapeutic drug monitoring device to maximize drug adherence.
ST-103 – FDA approval of higher dose dual-drug pill coupled with a therapeutic drug monitoring device to treat familial hypercholesterolemia.
Kybiqo is being developed for the treatment of combined hypercholesterolemia and hypertension. Olmesartan medoxomil is marketed as Benicar® tablets by Daiichi-Sankyo, Inc. and rosuvastatin calcium is marketed as Crestor® tablets by AstraZeneca Pharmaceuticals, LP.
Kybiqo is the same drug treatment as Olostar® which is now marketed in South Korea by Daewoong Pharmaceuticals Co. Ltd.,– a company incorporated under the laws of South Korea (“Daewoong”). The dose strength of ST-101, 40/20, 20/20, 20/10 and 20/5 (mg of olmesartan medoxomil/mg of rosuvastatin calcium), is the same dose strength as Olostar®, commercialized in South Korea.
In April 2014, Daewoong’s dual-drug pill containing the active pharmaceutical ingredients olmesartan medoxomil and rosuvastatin calcium was approved in South Korea and is marketed by Daewoong as Olostar®.
The Company has recently obtained the rights to Daewoong’s dual-drug pill for development and marketing in the United States, Canada, Japan, Taiwan and Australia.
Stocosil plans to submit a 505(b)(2) New Drug Application (NDA) to obtain regulatory approval in the United States for the treatment of combined hypertension and hyperlipidemia using data from three South Korean clinical studies conducted by Daewoong as well as bridging studies demonstrating similar pharmacokinetics and pharmacodynamics (PK/PD) among Caucasian and South Korean populations.
Mr. Pyng Soon has been our Chief Executive Officer, Chief Financial Officer and Secretary since December 2014. From July 2009 to December 31, 2014, he was an in house general counsel of EFT Holdings, Inc., a public company traded in OTC BB. Mr. Soon has previously held positions with large public companies and accounting firms, including Yokohama Tire Corporation, KPMG, and Murchison and Cumming, LLP.
Dr. Trieu has been involved in drug discovery and development for over 20 years and has directly supported seven drug candidates from preclinical to clinical to commercialization.
Previously, he served at Parker Hughes Center as director of Cardiovascular Biology program that evaluated a series of small molecules and biologics against preclinical models of atherosclerosis, dyslipidemia, stroke, ALS, and restenosis. Dr. Trieu has 34 peer-reviewed scientific articles and has 25 issued patents and 62 patent applications.
Dr. Park has more than 15 years of biologics R&D and leadership experience across diverse biotech and pharma settings.
Previously, he was President and CEO of MabPrex leading the pharmaceutical development of therapeutic drug candidates. He was also President of Pharmaceutical Development at IgDraSol leading the CMC group and bringing manufacturing of drug products to FDA standards. Dr. Park also has held positions at Applied Molecular Evolution, Eli Lilly, and aTyr Pharma. Dr. Park received his doctorate in Biochemistry from Korea University and he completed postdoctoral training at Stanford University School of Medicine.
Dr. D’Cruz has over 15 years of preclinical drug development experience in academic and biopharmaceutical settings.
Dr. D’Cruz has held positions at Abraxis BioScience, Celgene, Children’s Hospital Los Angeles, Igdrasol/Sorrento Therapeutics, and Paradigm Pharmaceuticals.
He has over 120 peer-reviewed scientific publications, 95 scientific presentations in national and international meetings, 18 issued US patents and 13 peer-reviewed research grants from the NIH.